

June 18, 2013

VIA ECF

Hon. Lois H. Goodman, U.S.M.J. U.S. District Court for the District of New Jersey Clarkson S. Fisher Federal Building & U.S. Courthouse 402 East State Street Trenton, New Jersey 08608

John E. Flaherty
Partner
T. 973.639.7903
F. 973.297.3971
jflaherty@mccarter.com

Re: Orexo AB v. Mylan Pharmaceuticals Inc., et al., Civil Action No. 11-3788 (FLW) (LHG)

Dear Judge Goodman:

McCarter & English, LLP Four Gateway Center 100 Mulberry Street Newark, NJ 07102-4056 T. 973.622.4444 F. 973.624.7070 www.mccarter.com Our firm, along with our co-counsel Milbank, Tweed, Hadley & McCloy LLP, represents Plaintiff Orexo AB in the above-referenced matter. We write to inform the Court that Orexo has decided not to file a brief in opposition to Defendants' Motion for Leave to File Its First Amended Answer to Complaint, Separate Defenses, and Counterclaims. In light of the Court's reasoning and order during the June 17, 2013 teleconference permitting discovery relating to inequitable conduct while Mylan's motion to add that defense is pending, Orexo believes it will be more efficient for the parties to direct their attention towards completing discovery at this time. Orexo maintains that Mylan's allegations are factually deficient and legally baseless, and should have never been asserted. Orexo intends to seek summary judgment that there has been no inequitable conduct after the parties complete discovery.

BOSTON

Respectfully submitted,

HARTFORD

s/John E. Flaherty

NEW YORK

John E. Flaherty

cc: Counsel of Record (via email)

NEWARK

PHILADELPHIA

STAMFORD

WILMINGTON